{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:26:08Z","timestamp":1781223968280,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bbmt.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T20:57:07Z","timestamp":1467061027000},"page":"1773-1780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Westfall","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-5538","authenticated-orcid":false,"given":"Daniel","family":"Eastwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Shillingburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Esselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham Sebastian","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.06.016_bib0010","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","article-title":"Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation","volume":"77","author":"Philip","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0015","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3109\/07853890.2014.952662","article-title":"Autologous hematopoietic cell transplantation: an update for clinicians","volume":"46","author":"Hamadani","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0020","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","article-title":"Improving stem cell mobilization strategies: future directions","volume":"43","author":"Bensinger","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0030","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.bmt.1705298","article-title":"Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation","volume":"37","author":"Pavone","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0040","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0045","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0050","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21280","article-title":"Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF","volume":"28","author":"Chaudhary","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0055","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","article-title":"Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies","volume":"48","author":"Awan","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0060","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0065","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0080","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0085","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering","volume":"5","author":"Sutherland","year":"1996","journal-title":"J Hematother"},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2016.06.016_bib0095","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1007\/s00277-003-0764-4","volume":"82","author":"Link","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2014.318","article-title":"Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis","volume":"50","author":"Dhakal","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0105","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jcyt.2015.09.002","article-title":"Hematopoietic progenitor cell mobilization with \u201cjust-in-time\u201d plerixafor approach is a cost-effective alternative to routine plerixafor use","volume":"17","author":"Veltri","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0902-4441.2004.00171.x","article-title":"Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis","volume":"72","author":"Olivieri","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bmt.1704466","article-title":"Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma","volume":"33","author":"Kuittinen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0120","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1705239","article-title":"ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients","volume":"37","author":"Akhtar","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 4","key":"10.1016\/j.bbmt.2016.06.016_bib0130","doi-asserted-by":"crossref","first-page":"iv18","DOI":"10.1093\/annonc\/mdj994","article-title":"Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive\/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study","volume":"17","author":"Corazzelli","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.03.030","article-title":"Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with DLBCL","author":"Lisenko","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0140","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1038\/bcj.2014.79","article-title":"Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients","volume":"4","author":"Clark","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0145","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.016_bib0150","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116301732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116301732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T23:19:10Z","timestamp":1718666350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116301732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1083879116301732"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}